.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
Harvard Business School
Merck
Accenture
McKesson
Argus Health
Cantor Fitzgerald
Cerilliant
Baxter

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Peptides-containing liposomal surfactants
Abstract:The present invention discloses useful surfactant molecules including polypeptides, proteins, and a variety of other organic molecules, as well as methods of making and using same. Surfactant compositions, including liposomal surfactant compositions, are also disclosed. In one preferred embodiment, a pulmonary surfactant composition comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising about 10 to 60 amino acid residues, wherein the polypeptide includes a sequence constituted by alternating groupings of charged amino acid residues and uncharged amino acid residues.
Inventor(s): Cochrane; Charles G. (La Jolla, CA), Revak; Susan D. (San Diego, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Filing Date:Jun 07, 1995
Application Number:08/488,123
Claims:1. A polypeptide comprising at least 10 amino acid residues and no more than 60 amino acid residues, said polypeptide represented by the formula (Z.sub.a J.sub.b).sub.c Z.sub.d, wherein: Z is an amino acid residue independently selected from the group consisting of R, D, E, and K; J is an .alpha.-aminoaliphatic carboxylic acid selected from the group consisting of .alpha.-aminobutanoic acid, .alpha.-aminopentanoic acid, .alpha.-amino-2-methylpropanoic acid and .alpha.-aminohexanoic acid; a is 1 to 5; b is 3 to 20; c is 1 to 10; d is 0 to 3,

and wherein said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forms a pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

2. A compound to claim 1 wherein said phospholipid is present in the range of 50-100 weight percent, in a polypeptide:phospholipid weight ratio in the range of 1:7 to 1:1,000.

3. A compound according to claim 1 wherein said phospholipid is selected from the group consisting of: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (dipalmitoylphosphatidylcholine, DPPC); phosphatidyl glycerol (PG); and an admixture of DPPC and PG in a weight ratio of about 3:1.

4. A compound according to claim 1 further comprising palmitic acid, wherein said phospholipid comprises 50-90 weight percent and said palmitic acid comprises the remaining 10-50 weight percent of the lipid portion of said surfactant.

5. A liposomal surfactant composition prepared from a polypeptide comprising at least 10 amino acid residues and no more than 60 amino acid residues, said polypeptide including a sequence having alternating groupings of amino acid residues represented by the formula (Z.sub.a J.sub.b).sub.c Z.sub.d, wherein: Z is an amino acid residue independently selected from the group consisting of R, D, E, and K; J is an .alpha.-aminoaliphatic carboxylic acid selected from the group consisting of .alpha.-aminobutanoic acid, .alpha.-aminopentanoic acid, .alpha.-amino-2-methylpropanoic acid and .alpha.-aminohexanoic acid; is 1 to 5; b is 3 to 20; c is 1 to 10; and d is 0 to 3.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Chubb
Harvard Business School
Federal Trade Commission
Accenture
Colorcon
McKinsey
Deloitte
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot